Predicting 30-day major adverse cardiovascular events after primary percutaneous coronary intervention. The RISK-PCI...

Area of Science:

• Cardiology
• Clinical Risk Prediction
• Interventional Cardiology

Background:

• Identifying patients at risk for major adverse cardiovascular events (MACE) is crucial for optimizing treatment and discharge strategies post-primary percutaneous coronary intervention (pPCI).
• Risk stratification aids in selecting appropriate candidates for aggressive therapies or early discharge.
• Current risk assessment tools may require refinement for this specific patient population.

Purpose of the Study:

• To develop and validate a novel risk prediction model for 30-day MACE in patients undergoing pPCI.
• To identify independent predictors of MACE in this cohort.
• To create a practical risk score for clinical decision-making.

Main Methods:

• The observational RISK-PCI trial included 2096 patients undergoing pPCI (2006-2009).
• Patients were randomly assigned to derivation (80%) and validation (20%) sets.
• Multivariable logistic regression identified independent predictors, and a weighted score was calculated to define risk classes.

Main Results:

• The RISK-PCI score incorporates 12 independent predictors of 30-day MACE.
• A 125-fold increase in MACE was observed across risk score strata (≤1 to ≥15).
• The model demonstrated strong predictive performance (c-statistic 0.83 for MACE, 0.87 for death) and good calibration, with 30-day MACE incidence ranging from 1.9% (low risk) to 39.4% (very high risk).

Conclusions:

• A novel risk model, the RISK-PCI score, accurately predicts 30-day MACE following pPCI.
• This score can assist clinicians in personalizing treatment strategies based on patient-specific risk.
• The model's validated performance supports its utility in clinical practice for risk stratification.